IL-1β
Central pathogenic driver
- Expression
- Elevated
- Evidence level
- established
- Targeted by
- Anakinra, Canakinumab
Role in pathogenesis
IL-1β is the key cytokine driving Schnitzler inflammation. Proven by the dramatic, rapid response to anakinra — symptoms resolve within hours, confirming IL-1β as the effector molecule.
Targeting drugs (2)
| Drug | Mechanism | Response | Line |
|---|---|---|---|
| Anakinra | IL-1 receptor antagonist | ~94% | 1st |
| Canakinumab | Anti–IL-1β monoclonal antibody | High (RCT confirmed) | 2nd |